Cluster-Randomized Controlled Trial of Reducing Seclusion and Restraint in Secured Care of Men With Schizophrenia
Supplemental Material
850_ds001.pdf (29 KB)
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.
Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.
×850_ds001.pdf (29 KB)
This project was funded by the Finnish Ministry of Health through the developmental fund for Niuvanniemi Hospital. This study would not have been possible without the help and information from Dr. Kevin A. Huckshorn, Dr. Janice Lebel, and the leaders and staff of the state hospitals in Pennsylvania and South Florida.
Dr. Tiihonen is a member of the AstraZeneca and Janssen-Cilag advisory boards. He also reports serving as a consultant for or receiving fees for expert opinions or lectures from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffman–La Roche, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Novartis, Organon, and Pfizer. The other authors report no competing interests.